Omaveloxolone ameliorates isoproterenol-induced pathological cardiac hypertrophy in mice

Xianchao Li, Yang Wu, Yunzhao Yang, Yaohua Wu, Xi Yu & Wenjuan Hu (2023) Omaveloxolone ameliorates isoproterenol-induced pathological cardiac hypertrophy in mice, Free Radical Research, DOI: 10.1080/10715762.2023.2299359 

The cardioprotective effect of omaveloxolone was directly related to the activation of the Nrf2 signaling. In summary, our study identified that omaveloxolone may be a promising therapeutic agent to mitigate pathological cardiac hypertrophy.